Jazz Pharmaceuticals JAZZ Exercised (in shares)
Exercised (in shares) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's exercised (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's exercised (in shares)?
- Jazz Pharmaceuticals (JAZZ) reported exercised (in shares) of $134.51 in Q4 2025.
- How has Jazz Pharmaceuticals's exercised (in shares) changed year-over-year?
- Jazz Pharmaceuticals's exercised (in shares) increased by 16.1% year-over-year, from $115.81 to $134.51.
- What does exercised (in shares) mean?
- The total number of shares granted or issued through employee equity programs.
- How do you interpret exercised (in shares)?
- High issuance volumes signal significant reliance on equity for compensation, which may impact future earnings per share through dilution.
- How does exercised (in shares) compare across companies?
- Standard metric for assessing the scale of equity-based incentive programs across the industry.